Literature DB >> 8930399

A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780.

H Huynh1, X F Yang, M Pollak.   

Abstract

Insulin-like growth factors (IGFs) are potent mitogens for breast cancer cells. Although IGF-binding proteins (IGFBPs) are known to regulate access of IGFs to IGF receptors, their precise biological actions are poorly defined. We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors in vivo. In vitro studies showed that growth inhibition of MCF-7 human breast cancer cells induced by ICI was associated with increased transcription of the IGFBP-5 gene, increased IGFBP-5 mRNA abundance, and increased IGFBP-5 protein accumulation in the conditioned medium. Growth stimulation following estradiol exposure was associated with opposite effects. An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore, this antisense oligodeoxynucleotide attenuated both antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth inhibition. These data demonstrate that estradiol down-regulates and ICI up-regulates an autocrine IGFBP-5 growth inhibitory pathway in MCF-7 cells and suggest that IGFBP-5 plays a role in modulation of proliferation of breast cancers by estrogens and antiestrogens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930399

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  13 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  IGFBP-2 and -5: important regulators of normal and neoplastic mammary gland physiology.

Authors:  James Beattie; Yousef Hawsawi; Hanaa Alkharobi; Reem El-Gendy
Journal:  J Cell Commun Signal       Date:  2015-02-03       Impact factor: 5.782

3.  Alcohol exposure in utero leads to enhanced prepubertal mammary development and alterations in mammary IGF and estradiol systems.

Authors:  Tiffany A Polanco; Catina Crismale-Gann; Wendie S Cohick
Journal:  Horm Cancer       Date:  2011-08       Impact factor: 3.869

Review 4.  The role of mammary stroma in modulating the proliferative response to ovarian hormones in the normal mammary gland.

Authors:  T L Woodward; J W Xie; S Z Haslam
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

5.  Fetal alcohol exposure increases mammary tumor susceptibility and alters tumor phenotype in rats.

Authors:  Tiffany A Polanco; Catina Crismale-Gann; Kenneth R Reuhl; Dipak K Sarkar; Wendie S Cohick
Journal:  Alcohol Clin Exp Res       Date:  2010-11       Impact factor: 3.455

Review 6.  Role of insulin-like growth factor-binding proteins in the pathophysiology and tumorigenesis of gastroesophageal cancers.

Authors:  Manoj K Kashyap
Journal:  Tumour Biol       Date:  2015-09-14

Review 7.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 8.  The potential role of somatostatin analogues in breast cancer treatment.

Authors:  M Pollak
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec

9.  Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells.

Authors:  S S Larsen; I Heiberg; A E Lykkesfeldt
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

Review 10.  Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer.

Authors:  Mustafa Akkiprik; Yumei Feng; Huamin Wang; Kexin Chen; Limei Hu; Aysegul Sahin; Savitri Krishnamurthy; Ayse Ozer; Xishan Hao; Wei Zhang
Journal:  Breast Cancer Res       Date:  2008-08-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.